63.58
+0.36(+0.57%)
Currency In USD
| Previous Close | 63.22 |
| Open | 63.16 |
| Day High | 64 |
| Day Low | 62.25 |
| 52-Week High | 86.53 |
| 52-Week Low | 43.7 |
| Volume | 125,243 |
| Average Volume | 41,118 |
| Market Cap | 2.07B |
| PE | -46.75 |
| EPS | -1.36 |
| Moving Average 50 Days | 61.84 |
| Moving Average 200 Days | 61.98 |
| Change | 0.36 |
If you invested $1000 in Belite Bio, Inc (BLTE) since IPO date, it would be worth $6,003.78 as of July 15, 2025 at a share price of $63.58. Whereas If you bought $1000 worth of Belite Bio, Inc (BLTE) shares 2 years ago, it would be worth $4,400 as of July 15, 2025 at a share price of $63.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
GlobeNewswire Inc.
Jul 02, 2025 7:00 AM GMT
- 500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development
Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease
GlobeNewswire Inc.
May 21, 2025 7:00 AM GMT
Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant’s efficacy and favorable safety profileTrial completion expected by Q4 2025 (including a three-month follow-up period)Tinlarebant has previous
Belite Bio to Participate in Four Upcoming Investor Conferences
GlobeNewswire Inc.
May 12, 2025 12:00 PM GMT
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medi